Humanigen, Inc. HGEN
0.00 USD 0.00 (+0.00%)
As ofJan 4, 2024, 1:45 PM EST
0.0001 Day range 0.0005
0.0001 52-week range 0.239
- EPS (ttm)
- -0.51
- P/E ratio
- -0.00
- Volume
- 2.06M
- Avg volume
- 341.85K
- Open
- 0.0005
- Previous close
- 0.0002
- Day's range
- 0.0001 – 0.0005
- 52-week range
- 0.0001 – 0.239
No chart data for this range yet.
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Financials — quick view
HGEN Revenue — quarterly 221.00K
HGEN Net income — quarterly -4.18M
HGEN EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 1, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
| Oct 6, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.21 | — | — | — |
| Aug 12, 2022 | Jun 1, 2022 | -0.34 | — | — | — |
News
US says former Humanigen chief scientific officer charged with insider trading 
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement 
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement 
HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy 
COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy 
Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation 
Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy 
Stocks That Hit 52-Week Lows On Tuesday 
Why Is Humanigen (HGEN) Stock Down 72% Today? 
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Your note
Sign in to keep a note on HGEN — it syncs with the Stock Master app.